CytoMed Therapeutics Limited GDTC
0.77 USD -0.06 (-6.87%)
Regular-session close
0.77 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
0.73 Day range 0.8499
0.68 52-week range 2.12
- YTD
- -42.31%
- 1 year
- -57.29%
News
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session Gainers MaxCyte (NASDAQ:MXCT) stock increased by 21.4% to $1.53 during Monday's pre-market session. The market value of their outstanding shares is at $130.0 million. Vir Biotechnology (NASDAQ:VIR)…
defenseworld.net CytoMed Therapeutics (NASDAQ:GDTC) Shares Down 11% – Here’s What Happened CytoMed Therapeutics Limited (NASDAQ: GDTC - Get Free Report)'s stock price dropped 11% during trading on Monday. The company traded as low as $0.8650 and last traded at $0.89. Approximately 33,556…
defenseworld.net CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 7.2% – Here’s Why CytoMed Therapeutics Limited (NASDAQ: GDTC - Get Free Report)'s stock price was up 7.2% on Thursday. The stock traded as high as $1.67 and last traded at $1.67. Approximately 32,493 shares traded…
seekingalpha.com CytoMed Therapeutics Limited (GDTC) Q2 2025 Earnings Call Prepared Remarks Transcript CytoMed Therapeutics Limited (NASDAQ:GDTC ) Q2 2025 Earnings Call October 2, 2025 10:00 AM EDT Company Participants Yvonne Goh - Chief Financial Officer Presentation Yvonne Goh Chief Financial…
globenewswire.com CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its…
globenewswire.com Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition SINGAPORE, Aug. 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its…
globenewswire.com CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program SINGAPORE, Aug. 18, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its…
globenewswire.com Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies SINGAPORE, July 21, 2025 (GLOBE NEWSWIRE) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a…
globenewswire.com CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates SINGAPORE, April 28, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on…
globenewswire.com CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders SINGAPORE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”) today released a letter to shareholders from the Chairman of the Company's Board…
benzinga.com Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor On Monday, CytoMed Therapeutics GDTC stock is down 6.35% at $3.23 at last check Monday.
globenewswire.com Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now MIAMI, Aug. 20, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 74th Emerging Growth Conference on August 21 – 22, 2024.
globenewswire.com CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology Another Patent Granted for CytoMed's…
accesswire.com CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company that focuses on utilizing its licensed…
globenewswire.com CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary…
globenewswire.com CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary…
globenewswire.com Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology The Company now has exclusive rights to a Malaysia, US and China patent The Company now has exclusive rights to a Malaysia, US and China patent
prnewswire.com CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology SINGAPORE , Dec. 5, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary…
prnewswire.com CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update Conference call webcast is scheduled for November 22 at 9 a.m. ET. SINGAPORE , Nov. 17, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based…
prnewswire.com CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference SINGAPORE , Nov. 14, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary…
accesswire.com CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed…
